{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:55:02Z","timestamp":1789836902895,"version":"4.0.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:00:00Z","timestamp":1496361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0178617","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T13:47:06Z","timestamp":1496411226000},"page":"e0178617","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is the efficacy of antidepressants in panic disorder mediated by adverse events? A mediational analysis"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5661-5149","authenticated-orcid":true,"given":"Irene","family":"Bighelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Borghesani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,6,2]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/00005053-199410000-00003","article-title":"A meta-analysis of fluoxetine outcome in the treatment of depression","volume":"182","author":"RP Greenberg","year":"1994","journal-title":"The Journal of nervous and mental disease"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1192\/bjp.bp.114.150136","article-title":"Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials","volume":"208","author":"M Barth","year":"2016","journal-title":"The British journal of psychiatry: the journal of mental science"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0165-1781(87)90057-6","article-title":"Baseline characteristics of 10-day placebo washout responders in antidepressant trials","volume":"21","author":"JG Rabkin","year":"1987","journal-title":"Psychiatry research"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1176\/ajp.149.12.1730","article-title":"Side effects and the &quot;blindability&quot; of clinical drug trials","volume":"149","author":"K White","year":"1992","journal-title":"The American journal of psychiatry"},{"issue":"1\u20132","key":"ref5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0165-0327(98)00147-5","article-title":"Double-blindness procedure did not mask giving of medication in panic disorder","volume":"54","author":"A Bakker","year":"1999","journal-title":"Journal of affective disorders"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0005-7916(02)00013-7","article-title":"Penetrating the blind in a study of an SSRI","volume":"33","author":"MP Piasecki","year":"2002","journal-title":"Journal of behavior therapy and experimental psychiatry"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010828","article-title":"Antidepressants versus placebo for panic disorder in adults","author":"G Guaiana","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref8","unstructured":"American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)."},{"key":"ref9","unstructured":"World Health Organization (1992) The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10)."},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2008.08.009","article-title":"Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD","volume":"19","author":"GI Papakostas","year":"2009","journal-title":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1017\/S1121189X00001263","article-title":"A simple approach to manage dosages in drug-epidemiology research","volume":"17","author":"M Nose","year":"2008","journal-title":"Epidemiologia e psichiatria sociale"},{"key":"ref12","unstructured":"World Health Organization (2016) DDD Definition and general considerations."},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1037\/0022-3514.51.6.1173","article-title":"The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations","volume":"51","author":"RM Baron","year":"1986","journal-title":"Journal of personality and social psychology"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/archpsyc.59.10.877","article-title":"Mediators and moderators of treatment effects in randomized clinical trials","volume":"59","author":"HC Kraemer","year":"2002","journal-title":"Archives of general psychiatry"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1080\/10543406.2011.607736","article-title":"The bootstrap and Markov-chain Monte Carlo","volume":"21","author":"B Efron","year":"2011","journal-title":"Journal of biopharmaceutical statistics"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","article-title":"Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients","volume":"103","author":"GM Asnis","year":"2001","journal-title":"Psychiatry research"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1192\/bjp.187.4.352","article-title":"Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study","volume":"187","author":"J Bradwejn","year":"2005","journal-title":"The British journal of psychiatry: the journal of mental science"},{"key":"ref18","article-title":"A double-blind, multicentered, flexible-dose study of paroxetine, alprazolam A double-blind, multicentered, flexible-dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder","year":"1994","journal-title":"GSK Clinical Study Register"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4088\/JCP.08m04238","article-title":"A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder","volume":"70","author":"MR Liebowitz","year":"2009","journal-title":"The Journal of clinical psychiatry"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1192\/bjp.173.1.54","article-title":"Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation","volume":"173","author":"PD Londborg","year":"1998","journal-title":"The British journal of psychiatry: the journal of mental science"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/(SICI)1522-7154(1996)2:4<192::AID-ANXI6>3.0.CO;2-Q","article-title":"Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder","volume":"2","author":"NP Nair","year":"1996","journal-title":"Anxiety"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archpsyc.55.11.1010","article-title":"Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial","volume":"55","author":"MH Pollack","year":"1998","journal-title":"Archives of general psychiatry"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-007-0821-0","article-title":"A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder","volume":"194","author":"M Pollack","year":"2007","journal-title":"Psychopharmacology"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20218","article-title":"A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder","volume":"24","author":"MH Pollack","year":"2007","journal-title":"Depression and anxiety"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"SM Stahl","year":"2003","journal-title":"The Journal of clinical psychiatry"},{"issue":"19","key":"ref26","first-page":"639","article-title":"Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor for panic disorder: a double-blind, placebo-controlled trial","author":"S Tsutsui","year":"1997","journal-title":"Journal of Neuropsychopharmacology"},{"key":"ref27","first-page":"S271","article-title":"Clinical evaluation of paroxetine Hcl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder: late phase II double-blind, parallel group study","volume":"28","author":"S Tsutsui","year":"2000","journal-title":"Japanese Pharmacology and Therapeutics"},{"key":"ref28","first-page":"S295","article-title":"Clinical evaluation of paroxetine Hcl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder: phase III double-blind, parallel group study","author":"S Tsutsui","year":"2000","journal-title":"Japanese Pharmacology and Therapeutics"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1192\/bjp.179.6.514","article-title":"Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial","volume":"179","author":"D Michelson","year":"2001","journal-title":"The British journal of psychiatry: the journal of mental science"},{"key":"ref30","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT GS Higgins","year":"2011"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1192\/bjp.177.1.47","article-title":"Critical approach to antidepressant trials. Blindness protection is necessary, feasible and measurable","volume":"177","author":"C Even","year":"2000","journal-title":"The British journal of psychiatry: the journal of mental science"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"e1001530","DOI":"10.1371\/journal.pmed.1001530","article-title":"A new approach to psychiatric drug approval in Europe","volume":"10","author":"C Barbui","year":"2013","journal-title":"PLoS medicine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"b1025","DOI":"10.1136\/bmj.b1025","article-title":"Patients and the public deserve big changes in evaluation of drugs","volume":"338","author":"S Garattini","year":"2009","journal-title":"BMJ (Clinical research ed.)"},{"key":"ref34","first-page":"CD011567","article-title":"Antidepressants and benzodiazepines for panic disorder in adults","volume":"9","author":"I Bighelli","year":"2016","journal-title":"The Cochrane database of systematic reviews"},{"issue":"9","key":"ref35","first-page":"CD010828","article-title":"Azapirones versus placebo for panic disorder in adults","author":"H Imai","year":"2014","journal-title":"The Cochrane database of systematic reviews"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1017\/S2045796012000170","article-title":"What is the European Medicines Agency","volume":"21","author":"I Bighelli","year":"2012","journal-title":"Epidemiology and psychiatric sciences"},{"key":"ref37","unstructured":"(2010) Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available. EMA."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0178617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T09:51:42Z","timestamp":1569405102000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0178617"}},"subtitle":[],"editor":[{"given":"Shawn","family":"Hayley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,2]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0178617","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,2]]}}}